Third Annual Scripps Cardiomyopathy and Cardio-Oncology Symposium
The Role of Screening Tests in Cardiomyopathy: When to Order Genetic Tests or Screen for Arrhythmia
Dr. Ajay Srivastava reviews classifications of cardiomyopathies and the role of genetics when determining appropriate screening for patients.
Co-Director, Hypertrophic Cardiomyopathy (HCM) Clinic
Scripps Clinic
La Jolla, California
Cardio-Oncology 2020: What You Need to Know
Dr. Ronald Witteles discusses common cancer therapies and their ever-expanding list of associated cardio-toxicities while proposing a need to expand the specialty of Cardio-Oncology.
Co-Director, Stanford Amyloid Center
Stanford University Medical Center
Stanford, California
Cardiomyopathy and Cardio-Oncology Symposium: Case Presentations and Panel Discussion - Part 1
Faculty review real-life cases from their practice and answer questions from course participants (session 1 of 2).
Beyond Echocardiography: The Role of Multimodality Cardiac Imaging
Dr. Juan Lopez-Mattei discusses the efficacy of multimodality cardiac imaging in diagnosing and identifying cardiomyopathies.
Juan Lopez-Mattei, MD, FACC, FASE, FSCCT, FSCMR
Co-Director, Cardiac Radiology ServicesDepartment of Diagnostic Radiology
Associate Professor of Cardiology and Diagnostic Imaging
The University of Texas MD Anderson Cancer Center
Houston, Texas
Cardiac Amyloidosis: Diagnosis and Treatment Update
Dr Rajeev Mohan discusses the pathophysiology and epidemiology of cardiac amyloidosis, clinic features to be aware of, and current diagnostic and treatment strategies.
Scripps Clinic
La Jolla, California
Cardiomyopathy and Cardio-Oncology Symposium: Case Presentations and Panel Discussion - Part 2
Faculty review real-life cases from their practice and answer questions from course participants (session 2 of 2).Course Overview
The Scripps Cardiomyopathy and Cardio-Oncology Symposium is designed to provide a comprehensive, case-based curriculum that addresses important clinical topics relevant to cardiomyopathy and cardiovascular health of cancer survivors. Cardio-oncology is a growing field that has great importance as newly developed cancer treatments improve cancer survival rates but can be associated with cardiovascular toxicities. Cardiac amyloidosis, a burgeoning disease with exciting new treatments will also be discussed.
Educational Objectives
- Assess the risks of oncologic treatment-related cardiac dysfunction for patients who have undergone therapy for cancer.
- Implement strategies for early detection, correction of cardiac risk factors, and close and long-term cardiac monitoring in order to reduce the effects of cardiotoxicity for patients who are at risk of cancer treatment-related cardiac dysfunction.
- Discuss the latest diagnosis and treatment options available for cardiac amyloidosis.
- Evaluate multi-modality imaging such as cardiac magnetic resonance (MR), echocardiography, and nuclear imaging including positron emission tomography (PET) scanning in the diagnosis and follow-up of cardiomyopathy.
Target Audience
- Cardiologists
- Oncologists
- Internists
- Nurse Practitioners
- Physician Assistants